Figures & data
Table 1 Summary of the most important studies used for this review
Parkinson Study GroupSafety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study GroupJAMA1997278125309214527 Parkinson Study GroupPramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study GroupJAMA20002841931811035889 ShannonKMBennettJPJrFriedmanJHEfficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study GroupNeurology19974972489305331 HollowayRGShoulsonIFahnSPramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trialArch Neurol20046110445315262734 LiebermanARanhoskyAKortsDClinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group studyNeurology19974916289222185 PinterMMPogarellOOertelWHEfficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre studyJ Neurol Neurosurg Psychiatry1999664364110201413 PinterMMRutgersAWHebenstreitEAn open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson’s diseaseJ Neural Transm200010713072311145006 BennettJPJrPierceyMFPramipexole – a new dopamine agonist for the treatment of Parkinson’s diseaseJ Neurol Sci1999163253110223406 WeinerWJFactorSAJankovicJThe long-term safety and efficacy of pramipexole in advanced Parkinson’s diseaseParkinsonism Relat Disord200171152011248592 WongKSLuCSShanDEEfficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson’s diseaseJ Neurol Sci200321681714607306 MollerJCOertelWHKosterJLong-term efficacy and safety of pramipexole in advanced Parkinson’s disease: results from a European multicenter trialMov Disord2005206021015726540 PoeweWHRascolOQuinnNEfficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trialLancet Neurol200765132017509486 GuttmanMDouble-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. International Pramipexole-Bromocriptine Study GroupNeurology199749106059339690 MizunoYYanagisawaNKunoSRandomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson’s diseaseMov Disord20031811495614534919 HannaPARatkosLOndoWGSwitching from pergolide to pramipexole in patients with Parkinson’s diseaseJ Neural Transm2001108637011261747 RektorovaIRektorIBaresMPramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized studyEur J Neurol20031039940612823492 GoetzCGBlasucciLStebbinsGTSwitching dopamine agonists in advanced Parkinson’s disease: is rapid titration preferable to slow?Neurology1999521227910214748 InzelbergRCarassoRLSchechtmanEA comparison of dopamine agonists and catechol-O-methyltransferase inhibitors in Parkinson’s diseaseClin Neuropharmacol200023262611154093 ReichmannHOdinPBrechtHMChanging dopamine agonist treatment in Parkinson’s disease: experiences with switching to pramipexoleJ Neural Transm Suppl2006172517447411 PogarellOGasserTvan HiltenJJPramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre studyJ Neurol Neurosurg Psychiatry2002727132012023411 NavanPFindleyLJJeffsJADouble-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson’s diseaseMov Disord2003a181768012539211 NavanPFindleyLJJeffsJARandomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremorMov Disord2003b1813243114639675 LemkeMRBrechtHMKoesterJEffects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson’s diseaseJ Neurol Sci20062482667016814808 GuttmanMJaskolkaJThe use of pramipexole in Parkinson’s disease: are its actions D(3) mediated?Parkinsonism Relat Disord20017231411331191 KumruHSantamariaJValldeoriolaFIncrease in body weight after pramipexole treatment in Parkinson’s diseaseMov Disord2006211972416972276 LemkeMRBrechtHMKoesterJAnhedonia, depression, and motor functioning in Parkinson’s disease during treatment with pramipexoleJ Neuropsychiatry Clin Neurosci2005172142015939976 ReichmannHBrechtMHKosterJPramipexole in routine clinical practice: a prospective observational trial in Parkinson’s diseaseCNS Drugs2003179657314533946 BrusaLBassiAStefaniAPramipexole in comparison to l-dopa: a neuropsychological studyJ Neural Transm20031103738012658365 ReljaMKlepacNA dopamine agonist, pramipexole, and cognitive functions in Parkinson’s diseaseJ Neurol Sci2006248251416797593 FantiniMLGagnonJFFilipiniDThe effects of pramipexole in REM sleep behavior disorderNeurology20036114182014638967 SchmidtMHKoshalVBSchmidtHSUse of pramipexole in REM sleep behavior disorder: results from a case seriesSleep Med200674182316815751 FruchtSRogersJDGreenePEFalling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropiniroleNeurology19995219081010371546 HauserRAGaugerLAndersonWMPramipexole-induced somnolence and episodes of daytime sleepMov Disord2000156586310928575 HappeSBergerKThe association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson’s disease – a prospective studyJ Neurol20012481062712013583 HobsonDELangAEMartinWRExcessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders GroupJAMA20022874556311798367 HomannCNWenzelKSuppanKSleep attacks in patients taking dopamine agonists: reviewBMJ20023241483712077032 O’SuilleabhainPEDeweyRBJrContributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson diseaseArch Neurol200259986912056935 EtminanMGillSSamiiAComparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson’s disease: a meta-analysisDrug Saf2003264394412688834 PausSBrechtHMKosterJSleep attacks, daytime sleepiness, and dopamine agonists in Parkinson’s diseaseMov Disord2003186596712784269 RazmyALangAEShapiroCMPredictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonistsArch Neurol2004619710214732626 AvornJSchneeweissSSudarskyLRSudden uncontrollable somnolence and medication use in Parkinson diseaseArch Neurol2005621242816087765 RomigiABrusaLMarcianiMGSleep episodes and daytime somnolence as result of individual susceptibility to different dopaminergic drugs in a PD patient: a polysomnographic studyJ Neurol Sci200522871015607203 BiglanKMHollowayRGJrMcDermottMPRisk factors for somnolence, edema, and hallucinations in early Parkinson diseaseNeurology2007691879517620552 ChaudhuriKRDhawanVBasuSValvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be sparedMov Disord2004191522315515009 JunghannsSFuhrmannJTSimonisGValvular heart disease in Parkinson’s disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography studyMov Disord200722234817094087 PeraltaCWolfEAlberHValvular heart disease in Parkinson’s disease vs. controls: An echocardiographic studyMov Disord20062111091316622856 YamamotoMUesugiTNakayamaTDopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control studyNeurology2006671225917030757 DeweyRB2ndReimoldSCO’SuilleabhainPECardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson diseaseArch Neurol2007643778017353380 SchadeRAndersohnFSuissaSDopamine agonists and the risk of cardiac-valve regurgitationN Engl J Med2007356293817202453 ZanettiniRAntoniniAGattoGValvular heart disease and the use of dopamine agonists for Parkinson’s diseaseN Engl J Med2007356394617202454 DoddMLKlosKJBowerJHPathological gambling caused by drugs used to treat Parkinson diseaseArch Neurol20056213778116009751 KlosKJBowerJHJosephsKAPathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson’s disease and multiple system atrophyParkinsonism Relat Disord200511381616109498 WeintraubDMoralesKHMobergPJAntidepressant studies in Parkinson’s disease: a review and meta-analysisMov Disord2005201161915954137 QuickfallJSuchowerskyOPathological gambling associated with dopamine agonist use in restless legs syndromeParkinsonism Relat Disord200713535617270485 MamikonyanESiderowfADDudaJELong-term follow-up of impulse control disorders in Parkinson’s diseaseMov Disord200823758017960796 NoyesKDickAWHollowayRGPramipexole v. levodopa as initial treatment for Parkinson’s disease: a randomized clinical-economic trialMed Decis Making2004244728515358996 Parkinson Study GroupPramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritageClin Neuropharmacol200730728517414939 TanEKOndoWClinical characteristics of pramipexole-induced peripheral edemaArch Neurol2000577293210815140 Kleiner-FismanGFismanDNRisk factors for the development of pedal edema in patients using pramipexoleArch Neurol200764820417420306